Literature DB >> 6465385

Reliability of criteria for borderline personality disorder: a comparison of DSM-III and the Diagnostic Interview for Borderline Patients.

A Frances, J F Clarkin, M Gilmore, S W Hurt, R Brown.   

Abstract

The authors compared the reliability of two methods of distinguishing borderline personality disorder--DSM-III and the Diagnostic Interview for Borderline Patients. The reference group, outpatients with other personality disorders and without major axis I pathology, was more difficult to distinguish from the patients with borderline personality disorder than such groups used in previous samples. The sensitivity and specificity of the Diagnostic Interview for Borderline Patients were calculated, with DSM-III used as a criterion. The findings confirm considerable overlap between borderline and schizotypal personality disorders, more impairment in functioning in borderline patients than in those with other personality disorders, and the high reliability with which borderline personality disorder can be diagnosed.

Entities:  

Mesh:

Year:  1984        PMID: 6465385     DOI: 10.1176/ajp.141.9.1080

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN: 0002-953X            Impact factor:   18.112


  10 in total

1.  The Personality Disorders Institute/Borderline Personality Disorder Research Foundation Randomized Control Trial for Borderline Personality Disorder: reliability of Axis I and II diagnoses.

Authors:  Kenneth L Critchfield; Kenneth N Levy; John F Clarkin
Journal:  Psychiatr Q       Date:  2007-03

2.  Borderline disorder in Turkey: a 2- to 4-year follow-up.

Authors:  S Senol; C Dereboy; N Yüksel
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  1997-02       Impact factor: 4.328

3.  Are there differences between borderline and other personality disorders?

Authors:  G Toffler; J Modestin
Journal:  Eur Arch Psychiatry Neurol Sci       Date:  1987

4.  Frequency of borderline personality disorder among psychiatric outpatients in Shanghai.

Authors:  Lanlan Wang; Colin A Ross; Tianhong Zhang; Yunfei Dai; Haiyin Zhang; Mingyi Tao; Jianying Qin; Jue Chen; Yanling He; Mingyuan Zhang; Zeping Xiao
Journal:  J Pers Disord       Date:  2012-06

5.  The course of substance use disorders in patients with borderline personality disorder and Axis II comparison subjects: a 10-year follow-up study.

Authors:  Mary C Zanarini; Frances R Frankenburg; Frances R Frankenbur; Jolie L Weingeroff; D Bradford Reich; Garrett M Fitzmaurice; Roger D Weiss
Journal:  Addiction       Date:  2010-11-18       Impact factor: 6.526

6.  The course of dysphoric affective and cognitive states in borderline personality disorder: a 10-year follow-up study.

Authors:  Lawrence Ian Reed; Garrett Fitzmaurice; Mary C Zanarini
Journal:  Psychiatry Res       Date:  2012-02-10       Impact factor: 3.222

7.  The relationship between childhood adversity and dysphoric inner states among borderline patients followed prospectively for 10 years.

Authors:  Lawrence Ian Reed; Garrett Fitzmaurice; Mary C Zanarini
Journal:  J Pers Disord       Date:  2013-02-27

8.  The Course of Positive Affective and Cognitive States in Borderline Personality Disorder: A 10-year Follow-up Study.

Authors:  Lawrence Ian Reed; Garrett Fitzmaurice; Mary C Zanarini
Journal:  Personal Ment Health       Date:  2012-11-01

9.  Prevalence, correlates, disability, and comorbidity of DSM-IV borderline personality disorder: results from the Wave 2 National Epidemiologic Survey on Alcohol and Related Conditions.

Authors:  Bridget F Grant; S Patricia Chou; Risë B Goldstein; Boji Huang; Frederick S Stinson; Tulshi D Saha; Sharon M Smith; Deborah A Dawson; Attila J Pulay; Roger P Pickering; W June Ruan
Journal:  J Clin Psychiatry       Date:  2008-04       Impact factor: 4.384

10.  Cognitive experiences reported by patients with borderline personality disorder and axis II comparison subjects: a 16-year prospective follow-up study.

Authors:  Mary C Zanarini; Frances R Frankenburg; Michelle M Wedig; Garrett M Fitzmaurice
Journal:  Am J Psychiatry       Date:  2013-06       Impact factor: 18.112

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.